CB2-specific inverse agonists have been reported to ameliorate bone damage in a rat model of relapsing–remitting arthritis [42] and have shown anti-inflammatory and anti-osteoclastogenic properties in activated macrophages and differentiating osteoclasts, respectively [43]. The gene discussed is CNR2; the disease is arthritic joint disease.